U.S. Logistics Stock News

Denali Therapeutics (NasdaqGS:DNLI) has regained full global rights to DNL593 for frontotemporal dementia granulin, after Takeda ended its collaboration. DNL593 uses Denali's TransportVehicle technology to deliver progranulin to the brain for patients with FTD-GRN. Denali plans to continue clinical development of DNL593 independently, with Phase 1/2 study results expected by the end of 2026. Denali Therapeutics focuses on treatments for neurodegenerative diseases, an area where current...

Why Hillman Solutions Is On Investors’ Radars Today Hillman Solutions (HLMN) is back in focus as investors weigh its recent share performance, with the stock roughly flat over the past month but showing a negative return over the past 3 months. Set against that backdrop, Hillman’s current market value of about US$1.62b, annual revenue of US$1.55b, and net income of US$40.31m give you a sense of the company’s scale in the hardware and home improvement products space. See our latest analysis...

In late March 2026, Baxter International Inc. introduced the IV Verify Line Labeling System in the U.S., an automated bedside labeling solution launched through an exclusive distribution agreement with Vigilant Software to help improve medication safety and nurse efficiency. By replacing handwritten IV line labels with standardized, color-coded and liquid-resistant barcoded labels, IV Verify targets a well-documented source of infusion errors and workflow burden in intensive care and other...

In early April 2026, EXL announced a collaboration with Google Cloud to expand AI-led transformation services, helping clients scale enterprise AI, modernize data, and upgrade cloud infrastructure across financial services, healthcare, life sciences, utilities, and retail. A key insight is that EXL is deepening its Google Cloud practice with over 800 trained AI specialists and proven frameworks already used to automate complex, high-volume workflows for large enterprises, particularly in...

This article examines whether Estée Lauder Companies is attractively priced after a difficult period in the market, or whether the stock could still face further downside, by focusing on what the current share price might imply about value. The stock last closed at US$69.12, with a 0.9% decline over 7 days, a 30.0% decline over 30 days, a 35.3% decline year to date, a 20.7% gain over 1 year, and declines of 69.7% over 3 years and 75.1% over 5 years. Together, these figures present a mixed...

In March 2026, Stryker reported a cyberattack that temporarily disrupted custom implant operations but, by late March, restored its electronic ordering system and most manufacturing capacity while maintaining product safety. With first-quarter 2026 results due on April 30, investors are watching how quickly Stryker’s operations normalize and what the incident reveals about its resilience and risk controls. We’ll now explore how Stryker’s rapid operational recovery from the cyberattack could...

Hexcel Corporation recently entered into a new US$750 million revolving credit facility maturing in 2031, drawing US$300 million to refinance its prior credit agreement without penalties and securing funds for general corporate uses, including acquisitions and investments. The new facility’s flexible structure, potential for up to US$500 million in additional commitments, and covenant framework reshapes Hexcel’s balance sheet options and risk profile ahead of its upcoming first-quarter 2026...

If you are wondering whether Toast's current share price is fair, expensive, or offers value, this article walks through the numbers so you can judge that for yourself. Toast shares last closed at US$26.47, with recent returns of 0.3% over 7 days, a 9.1% decline over 30 days, a 22.2% decline year to date, and a 19.0% decline over 1 year, while the 3 year return stands at 59.9%. Recent coverage has focused on Toast's position in the restaurant technology space and its ability to scale its...

Cencora (NYSE:COR) has signed a binding agreement to acquire the retina division of EyeSouth Partners, expanding its Retina Consultants of America network. The transaction centers on advanced retina care services and is intended to deepen Cencora's presence in ophthalmology-focused healthcare offerings. The company also announced the planned retirement of Chief Financial Officer James F. Cleary and has initiated an executive search for his successor. Cencora operates across pharmaceutical...

In late March 2026, activist short seller Morpheus Research released a report alleging that MakeMyTrip violated regulatory bans on price parity clauses and raised questions about accounting practices, including the treatment of a receivable from insolvent airline Go Air. The report also highlighted a large gap between MakeMyTrip’s adjusted profits and IFRS figures, bringing renewed attention to the company’s financial transparency and regulatory exposure. We’ll now explore how these...

KalVista Pharmaceuticals recently reported new interim results from its KONFIDENT-KID trial, showing that EKTERLY (sebetralstat) oral disintegrating tablets treated 172 hereditary angioedema attacks in 33 children aged 2–11 with rapid symptom relief and no serious or treatment-related adverse events. The data highlight how an easy-to-administer oral option could address a major gap in pediatric hereditary angioedema care, where current on-demand treatment for young patients in the US is...

Analyst downgrades and CEO exit put Adobe’s risk profile in focus Recent downgrades of Adobe (ADBE) and the planned retirement of long-serving CEO Shantanu Narayen have put leadership, pricing power, and AI competition at the center of the stock’s story for investors. Several research houses, including William Blair, have questioned how resilient Adobe’s Creative Cloud economics are as free or low cost design tools and AI native rivals gain traction, even as the company continues to invest...

CME Group (NasdaqGS:CME) reports record trading volumes across all product categories. The company launches 24/7 trading for regulated cryptocurrency futures and options. CME partners with BMO and Google Cloud to roll out 24/7 tokenized cash settlement for institutional clients. CME Group, trading at $305.11, is drawing attention after reporting all time record volumes across multiple asset classes and pushing further into round the clock trading. The stock is up 13.1% year to date and...

Millicom International Cellular: Recent Performance Snapshot Millicom International Cellular (TIGO) has caught investor attention after a strong run, with the stock showing gains over the past week, month and past 3 months that outpace its recent daily move. With a recent close of $79.64 and a market value of about $12.88b, investors are weighing this price action against Millicom’s reported $5,819.0 in revenue, $1,316.0 in net income and a value score of 5. See our latest analysis for...

Fermi Inc., in partnership with the Texas Tech University System, recently arranged up to US$156.25 million in unsecured debt financing alongside a US$165.00 million equipment loan, while advancing permitting and regulatory filings for its large-scale Project Matador energy campus in Texas. These moves, paired with a US$486.38 million net loss in 2025 and plans for up to ~17 GW of generation including nuclear, gas, solar, and batteries, highlight Fermi’s push to build a privately funded...

Eli Lilly (LLY) has surged back into the spotlight after the FDA approved Foundayo, a once daily oral GLP 1 pill for obesity that expands the company’s weight loss portfolio beyond injectables. See our latest analysis for Eli Lilly. The FDA approval of Foundayo comes after an already active period for Eli Lilly, with recent acquisitions in neuroscience and new data across dermatology and psoriatic arthritis. Over the same time, the share price has seen a 30 day return of 7.16% and a 90 day...

If you are wondering whether Pool's current share price lines up with its underlying value, this article walks through the numbers so you can judge that for yourself. Pool last closed at US$202.93, with returns of 0.9% over 7 days, an 8.3% decline over 30 days, an 11.7% decline year to date and a 34.1% decline over 1 year that many investors are watching closely. Over the past few months, coverage of Pool has focused on how the share price performance compares with broader retail...

Multiple law firms and investor groups have launched class action lawsuits against Nektar Therapeutics (NasdaqCM:NKTR). The suits allege securities fraud tied to protocol violations in the Phase 2b REZOLVE-AA trial. Claims focus on whether Nektar misled investors about enrollment and data integrity for this alopecia areata study. These legal actions introduce new uncertainty around the company’s clinical programs and governance practices. Nektar Therapeutics focuses on developing drug...

Comcast Xfinity is in a carriage dispute with E.W. Scripps that has triggered immediate blackouts of major broadcast networks and key sports programming in several U.S. markets. At the same time, Comcast has entered a partnership with NVIDIA to deploy real-time AI applications at the network edge across parts of its infrastructure. Both developments are material for NasdaqGS:CMCSA investors because they touch core video services, customer experience, and future network...

In late March 2026, On Holding AG announced a leadership shake-up effective May 1, 2026, with co-founders David Allemann and Caspar Coppetti becoming Co-CEOs, long-time CEO and former CFO Martin Hoffmann stepping down into an advisory role, and Frank Sluis joining as the new CFO. The reorganization places the founders directly in charge of day-to-day execution while elevating President & COO Scott Maguire to oversee the entire value chain, potentially tightening the link between product...

Why SEI Investments Is On Investors’ Radar Recent share performance has put SEI Investments (SEIC) back in focus for investors, with the stock showing a 7.2% decline over the past 3 months and a 6.8% decline over the past month. See our latest analysis for SEI Investments. The recent 1 day share price return of a 1.32% decline and a year to date share price return of a 7.23% decline contrast with a 1 year total shareholder return of 6.04%. This suggests that shorter term momentum has faded...

In late March 2026, FactSet Research Systems reported Q2 results showing higher sales than a year earlier, raised its full-year 2026 revenue and earnings guidance, continued buying back shares under its existing repurchase program, and advanced multiple AI initiatives including AI-enabled Document Search and the alpha launch of FactSet AI for Banking with Finster AI. These developments highlight FactSet’s effort to reposition itself as an AI-enabled data and workflow infrastructure provider,...

Rambus (RMBS) has come under pressure after two executives sold a combined US$4.6 million in stock in early March, a concentrated bout of insider selling that has unsettled some investors. See our latest analysis for Rambus. Despite the recent insider sales and sector weakness that pushed the share price lower in recent months, Rambus now trades at US$93.03, with a 6.21% 1 month share price return but a 6.30% share price decline year to date, set against a very large 101.58% 1 year total...

Citi recently raised its outlook on Cheniere Energy, highlighting how ongoing geopolitical disruption in the Middle East has reinforced long-term demand for secure U.S. LNG supplies, supported by the company’s expanding capacity and high contracted volumes through 2030. A key insight is that Cheniere is converting these geopolitical tailwinds into contracted cash flows, underlined by new long-dated deals such as its supply agreement with CPC Corporation of Taiwan running through 2050 and a...